XLXiumei Liu

Xiumei Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xiumei Liu has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Bo Wang

    Department of Toxicology, School of Public Health, Jilin University, 1163 Xinmin Avenue, Changchun, 130021, China

    1 shared publication
  • Chengqi Xin

    Stem Cell Clinical Research Center, National Joint Engineering Laboratory, Regenerative Medicine The First Affiliated Hospital of Dalian Medical University Dalian Liaoning China

    1 shared publication
  • Gang Yang

    College of Resources and Environment, Southwest University, Chongqing 400715, China

    1 shared publication
  • Jing Liu

    Department of Neonatology and NICU, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, China

    1 shared publication
  • Jinxiang Liu

    Beijing Institute of Technology

    1 shared publication
  • Kaiyu Yi

    Stem Cell Clinical Research Center, National Joint Engineering Laboratory, Regenerative Medicine The First Affiliated Hospital of Dalian Medical University Dalian Liaoning China

    1 shared publication

Latest Publications

  • Open Access

    Analysis of Somatic Mutations and Immunotherapy Biomarkers in Chinese Patients With Non‐Small Cell Lung Cancer During 2019–2024: A Retrospective Study

    by Xiumei Liu, Weigong Chen, Chengqi Xin, Zexu Wang, Kaiyu Yi, Liang Wang, Jing Liu

    Background and Aims: Understanding genetic alterations in lung cancer remains challenging due to tumor heterogeneity and malignancy. This study aimed to investigate somatic variations and immune‐related biomarkers in Chinese patients with NSCLC. Methods: This retrospective study involved Chinese patients with NSCLC from October 2019 to December 2024. A total of 554 pathological specimens were analyzed using targeted NGS panels. Fisher's exact test (two‐sided, 95% confidence interval) was applied to assess statistical significance. The functional impact of certain mutations was validated in lung cancer cell lines. Results: A total of 1302 genetic variations were identified. The most frequently altered genes included EGFR , TP53 , KRAS , PIK3CA , STK11 , ERBB2 , BRAF , CTNNB1 , MET , and PTEN . Enrichment analysis indicated that these genetic alterations were primarily concentrated in the EGFR, PI3K‐AKT, microRNAs, P53, MAPK, ErbB, VEGF, JAK‐STAT, and FoxO signaling pathways. Several co‐occurring and mutually exclusive mutations were identified among the top altered genes. The co‐mutation of PDGFRA and MET, or NRAS and PTEN in A549 cells, promoted cell proliferation and invasion compared with the control cells. Among patients receiving immunotherapy, the objective response rates were significantly higher in the TMB‐high group than in the TMB‐low group (62.5% vs. 34.2%), as well as in the heterozygous HLA‐I group compared to the homogenous HLA‐I group (51.6% vs. 25.9%). Analysis showed that TMB status was correlated with the tumor‐infiltrating immune cells in the TCGA LUAD and LUSC datasets. TP53 mutations were more prevalent in males ( p = 0.03) and associated with squamous cell carcinomas ( p = 0.007), whereas EGFR mutations were more common in females ( p < 0.001) and associated with lung adenocarcinomas ( p = 0.029). Conclusion: Our findings suggest that a high TMB combined with a heterozygous HLA‐I genotype serves as an effective biomarker for predicting the efficacy of immunotherapy in Chinese patients with NSCLC.

  • Klf4 could be activated by Pou5f3/Stat3 to induce the expression of Nanog in Japanese flounder

    by Yan Sun, Jinxiang Liu, Bo Wang, Xiumei Liu, Xinxin Du, Yuxiang Liu, Quanqi Zhang


  • Open Access

    Study on Conformation Interconversion of 3-Alkyl-4-acetyl-3,4-dihydro-2H-1,4-benzoxazines from Dynamic NMR Experiments and ab Initio Density Functional Calculations

    by Gang Yang, Xiuwen Han, Weiping Zhang, Xiumei Liu, Pengyu Yang, Yonggui Zhou, Xinhe Bao

    Variable-temperature NMR experiments and ab initio density functional calculations were carried out to investigate the conformation interconversion of novel chiral 3-alkyl-3,4-dihydro-2H-benzo[1,4]oxazine derivatives. With CDCl3 as the solvent, the coalescence temperatures of H2, H3, H11, and H19 of product 1 are about 289, 304, 292, and 316 K, with the corresponding activation free energies at 58.0 ± 6.7, 60.9 ± 7.1, 58.3 ± 6.8, and 59.6 ± 6.9 kJ·mol-1, respectively. When dimethyl sulfoxide (DMSO-d6) was used as the solvent, 1H and 13C NMR signals were completely assigned at 375 K. The effects of solvent and temperature were investigated through a polarizable continuum model. At each theoretical level (MP2 or B3LYP), the changing tendencies of the calculated activation free energies and interconversion rates agree well with those of the NMR results. In addition, the interconversion rate at each specified temperature was calculated to be about 1.5 times faster in DMSO-d6 than in CDCl3. Accordingly, we failed to observe the coalescence phenomena of H3 and H19 in DMSO-d6 by NMR measurements from 296 to 375 K. The substitution effect at the R1−R5 positions was considered using density functional calculations, with the activation barriers decreasing as follows: product 6 > 3 > 1 > 7 > 2. This sequence is consistent with that of the reaction heats, except for product 7, implying that the interconversion processes may be thermodynamically controlled. Surprisingly, the substituted groups near the acetyl group in product 2 and 7 do not elevate the activation barrier but, instead, lower it somewhat, with the possible reasons for this provided in the paper.